ANAB

AnaptysBio, Inc.

46.10 USD

Last updated Oct 13, 01:21 UTC

Yesterday HIGH

$47.19

Yesterday LOW

$45.81

52w HIGH

$73.3

52w LOW

$29.48

EPS

-0.11

PE

-419.09

Next Earnings

Nov 3, 2026

Overview News Unusual Options Flow Insider Transactions Government Trades Fundamentals

AnaptysBio, Inc. stock is down -14.42% since 30 days ago. The next earnings date is Nov 3, 2026. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 9 October’s closed higher than September. In the last 1 Unusual Options Trades, there were 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

01 Sep 18:38	18 Sep, 2026	50.00	PUT	362	1893

Advanced Data Unlock

Benzinga Newsdesk

Mon Apr 27, 2026

AnaptysBio shares are trading higher after a Delaware Chancery Court ruled in favor of the company in a breach of contract claim and left the current royalty rates paid to the company intact.
Avi Kapoor

Mon Apr 27, 2026

XOMA Royalty, Oruka Therapeutics, Repay Holdings And Other Big Stocks Moving Higher On Monday

U.S. stocks were lower, Dow Jones fell 0.1% on Monday. XOMA shares rose on Ligand's plans to acquire XOMA for $39.00/share. Other big gainers: MANE, ORKA, OGN, XE, PLBL, SLS, ANAB, EVH, IHRT, RPAY, JBIO, BEAM.
Benzinga Newsdesk

Fri Apr 24, 2026

AnaptysBio Wins Court Ruling Upholding Jemperli Royalties, Trial Vs. Tesaro/GSK Set For July 14–17, 2026

Ruling preserves current contracted royalty rates and rejects Tesaro's request for any royalty reductionTrial to adjudicate Anaptys' contract claims and right to seek reversion of Jemperli against Tesaro/GSK is scheduled
Benzinga Newsdesk

Fri Apr 24, 2026

Delaware Chancery Court Rules In Favor Of Anaptys By Dismissing Tesaro's Anticipatory Breach Claim; Court Ruling Preserves Current Royalty Rates And Rejects Tesaro's Royalty Reduction Request

Ruling preserves current contracted royalty rates and rejects Tesaro's request for any royalty reduction Trial to adjudicate Anaptys' contract claims and right to seek reversion of Jemperli against Tesaro/GSK is scheduled for July 14-17, 2026
Benzinga Newsdesk

Wed Apr 22, 2026

Barclays Maintains Overweight on AnaptysBio, Lowers Price Target to $63

Barclays analyst Etzer Darout maintains AnaptysBio (NASDAQ:ANAB) with a Overweight and lowers the price target from $79 to $63.
Benzinga Newsdesk

Tue Apr 21, 2026

UBS Maintains Buy on AnaptysBio, Lowers Price Target to $60

UBS analyst Michael Yee maintains AnaptysBio (NASDAQ:ANAB) with a Buy and lowers the price target from $90 to $60.
Benzinga Insights

Mon Apr 20, 2026

12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Newsdesk

Mon Apr 20, 2026

AnaptysBio shares are trading lower after the company announced it completed the spin-off of First Tracks Biotherapeutics
Benzinga Newsdesk

Mon Apr 20, 2026

AnaptysBio Completes Spin-Off Of First Tracks Biotherapeutics; Anaptys To Now Exclusively Manage Financial Collaborations For Jemperli With GSK And Imsidolimab With Vanda

Focused on protecting and returning value of Jemperli and imsidolimab royalties to shareholdersLaunches with virtual model, including limited FTEs and minimal operating expenses, and approximately $140-$145 million
Benzinga Insights

Mon Apr 20, 2026

12 Health Care Stocks Moving In Monday's Pre-Market Session

JP Morgan

Wed Sep 30, 20:02

buy

confirm
HC Wainwright & Co.

Thu Sep 24, 16:27

buy

confirm
Leerink Partners

Wed Sep 23, 15:14

buy

confirm

Advanced Data Unlock

HOLLINGS RENTON, Insider

Thu Oct 1, 2026

ANAB Recent Insider Trades and Stock Chart

5,000 shares sold
John Orwin, Insider

Tue Sep 15, 2026

ANAB Recent Insider Trades and Stock Chart

1,300 shares converted